Soluble ACE2 as a potential therapy for COVID-19.
Sudarshan KrishnamurthyRichard F LockeyNarasaiah KolliputiPublished in: American journal of physiology. Cell physiology (2021)
Soluble angiotensin-converting enzyme 2 (sACE2) could be a therapeutic option to treat coronavirus disease 2019 (COVID-19) infection. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) utilizes ACE2 receptors on cell surfaces to gain intracellular entry, making them an ideal target for therapy. High-affinity variants of sACE2, engineered using high-throughput mutagenesis, are capable of neutralizing COVID-19 infection as decoy receptors. These variants compete with native ACE2 present on cells by binding with spike (S) protein of SARS-CoV-2, making native ACE2 on cell surfaces available to convert angiotensin II to angiotensin-1,7, thus alleviating the exaggerated inflammatory response associated with COVID-19 infection. This article explores the use of sACE2 as potential therapy for COVID-19 infection.
Keyphrases
- angiotensin converting enzyme
- sars cov
- angiotensin ii
- respiratory syndrome coronavirus
- coronavirus disease
- single cell
- inflammatory response
- vascular smooth muscle cells
- high throughput
- cell therapy
- induced apoptosis
- copy number
- stem cells
- human health
- risk assessment
- transcription factor
- cell cycle arrest
- oxidative stress
- signaling pathway
- reactive oxygen species
- biofilm formation
- cystic fibrosis
- protein protein
- toll like receptor
- aedes aegypti
- dengue virus
- replacement therapy